The mechanism is now at the heart of a new therapeutic strategy for the treatment of DMD using different sequences of fully modified morpholino (morpholino: eteplirsen) and 2′-O-methyl-phosphorothioate RNA (drisapersen) oligonucleotides which induce exon skipping in the dystrophin mRNA. Here, DMD is linked to Duchenne muscular dystrophy.